Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University Innsbruck
This study investigates the safety and performance characteristics of the Direct Epicardial Shockwave Therapy System (DESWT) as applied with the Cardiac Shockwave Probe (CSP).
Age
21–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients between 21 and 90 years of age undergoing primary coronary artery bypass grafting
Presentation with reduced left ventricular function, defined as LVEF ≤ 40% measured by cardiac MRI
Presentation with regional left ventricular wall motion abnormalities
Written informed consent from the patient for participation in the study
You may not be if
Significant concomitant aortic valve disease requiring surgical treatment (other than significant aortic valve disease not detected in preoperative cardiac ultrasound but detected during surgery)
Serious radiographic contrast allergy
Patient in cardiogenic shock or presenting with acute myocardial infarction (STEMI or NSTEMI)
Patient with a contraindication for cardiac MRI
History of significant ventricular arrhythmia, other than MI-associated arrhythmia
Comorbidity reducing life expectancy to less than one year
